Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD, and Immunogenicity of Ricefidase (KJ103) in Healthy Subjects
NCT05274659Phase 1Completed
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
- Start
- May 2022
- Primary completion
- Mar 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ricefidase in kidney transplant rejection and autoimmune diseases (6 arms), sponsored by Shanghai Bao Pharmaceuticals Co., Ltd. Primary endpoint: Adverse Events (AE). Started May 2022; status: completed.
02
Drugs
ricefidase
03
Conditions
kidney transplant rejectionautoimmune diseases
Beyond the preview
Go deeper on NCT05274659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274659.